Ademović-Sazdanić D., S. Vojvodić, S. Popović, N. Konstantinidis (2017): Vojvodina, Vol 49, No.1,[345][346][347][348][349][350][351][352][353][354]. The outcome of HSCT is strongly influenced by the genetic similarity or identity in the HLA genes that affects the incidence of graft-versus-host disease (GvHD). Successful allogeneic HSCT, however, depends also on T-cell mediated graft-versus-leukemia (GvL) effect, in which donor-derived T cells and natural killer (NK) cells kill these malignant cells in the patient, therefore playing a crucial role in relapse prevention. The aim of this study was to make the predictive analysis of the structure and distribution of B KIR alleles and centromeric and telomeric KIR genotypes in HSCT donors in Vojvodina with regard to their contribution to protection from relapse. A total of 124 first-degree relatives of patients with hematological malignancies were examined for the presence or absence of 15 KIR genes by using of PCR-SSO technique with Luminex xMap technology. The percentage of individuals carrying each KIR gene, centromeric and telomeric KIR haplotypes and genotypes was determined by direct counting. Sixty two percent of the HSCT donors in Vojvodina carry A KIR haplotype, while nearly 38% carry B KIR 346 GENETIKA, Vol. 49, No.1, 345-354, 2017 haplotype. The distribution of B KIR genes showed that among 124 studied HSCT donors, 31(25%) do not carry none of the KIR genes belonging to B group, 71.77% of donors have two or more B KIR genes, 61.29% of them carry KIR 2DL2 and 2DS2 or more B KIR genes. The analysis of centromeric and telomeric KIR genotypes, showed that Cen-A1/Tel-A1 genotype had a highest frequency of 51.47% and Cen-B2/Tel-B1 the lowest frequency of 1.30%. The usage of donor KIR B gene content and centromeric and telomeric KIR gene structure could be used in development of a simple algorithm to identify donors who will provide the most protection against the relapse in related HSC transplants.
INTRODUCTION
Natural killer (NK) cells, which comprise 10-15% of all circulating lymphocytes, act as central components of the innate immune response, providing immediate defense against infectious agents and cancer. They also contribute to placentation and the success of reproduction (PYO et al., 2010; NEMAT-GORGANI et al., 2014; ASHOURI et al., 2009) . NK cells exert their functional effects by physically interacting with other types of cell, engagements that can lead to the killing of cells damaged by infection or malignancy, and to the secretion of cytokines that recruit other inflammatory immune system cells MIDDLETON and GONZALES, 2010) . As part of the mechanisms directing their effector functions, these cells utilize a number stimulatory and inhibitory receptors that in humans react with major histocompatibility complex (MHC) class I antigens (HLA-A, B, and C ligands) expressed by host cells. Of particular interest here is the diverse family of killer-cell immunoglobulin-like receptors (KIR) that recognize four mutually exclusive epitopes of the highly polymorphic HLA-A, HLA-B and HLA-C molecules. These epitopes comprise the A3/11 epitope carried by HLA-A*03 and HLA-A*11 allotypes, the Bw4 epitope carried by around one third of HLA-A and HLA-B allotypes, the C2 epitope carried by the subset of HLA-C allotypes having lysine at position 80, and the C1 epitope carried by the complementary subset of HLA-C allotypes that have asparagine at position 80 (NEMAT-GORGANI et al., 2014; HOU et al., 2012) .
Currently, 15 different KIR loci (KIR2DL1, KIR2DL2/KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1-5, KIR3DL1/KIR3DS1, KIR3DL2-3, and two pseudogenes, KIR2DP1 and KIR3DP1), have been identified (http://www.ebi.ac.uk/ipd/ kir/). Selected combinations of these genes are encoded on haplotypes within a 100-to 200-kb region of the Leucocyte Receptor Complex (LRC) located on human chromosome 19q13.4 (PYO et al., 2010; NEMAT-GORGANI et al., 2014; ASHOURI et al., 2009; PARHAM et al., 2012) . Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative treatment for many hematological malignancies. The outcome of HSCT is strongly influenced by the genetic differences between donor/recipient pairs (WARREN et al., 2012) . Genetic similarity or identity in the HLA genes in the major histocompatibility complex on chromosome 6, affects the incidence of graft-versus-host disease (GvHD), the major complication of HSCT. Successful allogeneic HSCT, however, depends also on T-cell mediated graft-versus-leukemia (GvL) effect, in which donor-derived T cells clear the remaining leukemic cells in patient. In addition to alloreactive T cells, donor-derived natural killer (NK) cells, are able to kill these malignant or virus-infected cells in the patient. NK cells might therefore have a crucial role in relapse prevention by destroying remaining acute myeloblastic leukemia cells (WARREN et al., 2012; FOLEY et al., 2014; VELARDI, 2008a (STERN et al., 2011) . Compared with A haplotype motifs, centromeric and telomeric B motifs both contributed to protection from relapse and improved survival, but Cen-B homozygosity had the strongest independent effect. With Cen-B/B homozygous donors the cumulative incidence of relapse was 15.4% compared with 36.5% for Cen-A/A donors (COOLEY et al., 2010) .The aim of this study was to make the predictive analysis of the structure and distribution of B KIR alleles and A/B KIR haplotypes in HSCT donors in Vojvodina with regard to their contribution to protection from relapse.
MATERIAL AND METHODS

Subjects
A total of 124 first-degree relatives [median age: 30 (1-60) years; male/female: 64/60] from 95 families with hematological malignant diseases were included in the study. The study protocol was approved by the Ethics Committee of the Clinical Center of Vojvodina. Donors were interviewed and an informed consent was received from all participants.
DNA purification
Genomic DNA was extracted from peripheral blood samples using silica-based method by either QIAamp blood mini kit (Qiagen GmbH, Hilden, Germany) or the GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific Inc., Vilnius, Lithuania). The quality and quantity of DNA samples were determined by UV spectrophotometry, and the concentration was adjusted to 100 ng/μl.
KIR genotyping and haplotype group assignment
The presence or absence of 15 KIR genes (KIR3DL3, KIR2DS2, KIR2DL2, KIR2DL3, KIR2DL5, KIR2DS3/2DS5, KIR2DP1, KIR2DL1, KIR3DP1, KIR2DL4, KIR3DL1, KIR3DS1, KIR2DS1, KIR2DS4 and KIR3DL2) was determined by the use of reverse sequence-specific oligonucleotide technique (Immucor Transplant Diagnostics, Inc., Stamford, Connecticut ) with Luminex xMap technology (Luminex Corp., Austin, TX). Donors were assigned the A/B, B/B or A/A genotype by their KIR gene content. Individuals having only genes of the group A KIR haplotypes (KIR3DL3-2DL3-2DL1-2DP1-3DP1-2DL4-3DL1-2DS4-3DL2) were considered to be homozygous for the A haplotype and assigned the KIR genotype AA. Individuals lacking any of the four A haplotype associated genes (KIR2DL1, 2DL3, 3DL1 and 2DS4 ) that have a known function and vary among individuals in their existence were regarded to be homozygous for group B haplotypes and assigned the KIR genotype BB. All other individuals were regarded to be heterozygous for A and B haplotypes and assigned the KIR genotype AB.
Genotypes for the centromeric (Cen) and telomeric (Tel) parts of the KIR locus were assigned according to the presence or absence of one or more B haplotype-defining KIR genes: Cen-A1, Cen-B1, Cen-B2, Tel-A1 and Tel-B1. As examples, Cen-A1 is comprised of KIR3DL3-KIR2DL3-KIR2DP1-KIR2DL1-KIR3DP1 in this gene order while Tel-A1 includes KIR2DL4-KIR3DL1-KIR2DS4-KIR3DL2 (MOESTA and PARHAM, 2012) ( 
Statistics
The percentage of individuals carrying each KIR gene, centromeric and telomeric KIR haplotypes and genotypes was determined by direct counting (individuals positive for the gene divided by the individuals tested per population×100). Frequencies of A and B haplotypes were calculated using the following formula: group A=2nAA+nAB/2N and group B=2nBB+nAB/2N, where nAA, nAB, and nBB were the numbers of AA, AB, and BB genotypes and N was the total number of individuals tested.
RESULTS
KIR gene frequency distribution
All 15 known KIR genes were detected in HSCT donors analyzed in this study, and two of four framework KIR genes (3DL3 and 3DP1) were detected in all 124 individuals analyzed, where the gene frequency was 1. KIR 3DL2, 2DL4, 2DL1 and 3DL1 genes were common with gene frequency of 0.983, 0.967, 0.959, and 0.935, respectively. KIR 2DP1, 2DS4, 2DL3, 2DS2 and 2DL2 genes were less common with frequencies of 0.951, 0.903, 0.854, 0.637 and 0.629, respectively. The KIR 2DS3 and 2DS5 gene frequencies were the lowest at 0.354 and 0.225, respectively ( 
Centromeric and telomeric KIR haplotypes and genotypes distribution
The distribution of telomeric and centromeric KIR haplotypes revealed that nearly 80% of HSCT donors in Vojvodina carried KIR2DL4-3DL1-2DS4-3DL2 gene cluster and 60.5% of donors carried KIR 3DL3-2DL3-2DP1-2DL1-3DP1 gene cluster, respectively. Among all existing centromeric KIR haplotypes, Cen-B2 was present in the lowest frequency among HSCT donors of 13.7% (Table 4 ). The analysis of centromeric and telomeric KIR genotypes among studied donors showed that A haplotype genes of the centromeric region in combination with Tel-A of the telomeric region (Cen-A1/Tel-A1) had a highest frequency of 51.47%.The lowest frequency was observed for Cen-B2/Tel-B1 KIR genotype with frequency of 1.30% (Table 5) . 
Assignments the donors to one of 3 groups based on KIR B-content
We determined KIR B-content scores for all donors according to the system proposed by Cooley et al. that is available at (www.ebi.ac.uk/ipd/kir/donor_b_content.html). These results were condensed according to the Donor KIR B-content group calculator (neutral  score of 0, better  score of 1 or 2, best  score of 3 or 4). Seventy-four (59.67%) donors had a neutral score, 33 (26.63%) had a score of 1/2, and 17 (13.70%) had a score of 3/4, respectively. DISCUSSION Diversity in human KIR genotype is sum from three components: haplotypic gene content, allelic polymorphism and the combination of maternal and paternal haplotypes. The combined effects of these three components are such that unrelated individuals usually differ in KIR genotype and ethnic populations have widely differing KIR genotype frequencies. Overall, the frequencies of the inhibitory KIR genes were higher and more homogeneous among worldwide populations than for the activating genes and KIR gene frequencies in the studied HSCT donors are in agreement with the predominantly European populations (KAMENARIĆ BUREK et al.,2013; DJULEJIĆ et al.,2010; BONTADINI et al., 2006; GUINAN et al.,2010) .
Since the patients transplanted from donors homozygous for KIR haplotype A had a greater risk of developing grade II-IV acute GVHD compared with those transplanted from a donor carrying at least one B haplotype (COOLEY et al., 2010) it is developed an interesting and innovative algorithm based on the number of donor KIR haplotype B motifs (score from 0 to 4). Donor high KIR B-content score is in association with better probability of event free survival (EFS) and lower relapse risk (COOLEY et al., 2010; LITERA et al., 2011; OEVERMANN et al., 2014) . Our result showed that although 0.80% donors carry BB KIR genotype, 74.1% of them carry A/B genotype with relively very high percentage of donors carrying at least KIR2DL2 and 2DS2, that are in association with statistically significant longer relapse-free survival (P = 0.015) in the patients with AML whose donors have KIR2DL2 or KIR2DS2 (IMPOLA et al., 2014) . Nearly 27% of donors have better score and nearly 14%, the best B KIR score, respectively.
Since the best outcome is observed for patients transplanted from donors with KIR Bcontent score 2 or greater (COOLEY et al., 2010; LITERA et al., 2011) and that B haplotype genes of the centromeric region had a stronger effect in improving the outcome of transplantation than those of the telomeric region (COOLEY et al., 2010) our results showed that among all studied HSCT donor, 13.99% were Cen-B/B homozygous. When the number of activating KIR genes present in the donors was taken into account, where grafts from the donors carrying ≥ 3 activating KIR genes provide significant protection from transplant related mortality (TRM) and significantly better EFS compared with A haplotype donors (TRM: 12 vs. 67%, p<0.003) (EFS: 71 vs. 33%, p=0.02) (VELARDI et al., 2008b) , our results showed that 39 (31.45%) of donors carried ≥ 3 activating KIR genes.
CONCLUSION
In conclusion, an accurate evaluation of the complexity of the KIR gene system, together with adopting the practice of usage of donor KIR B gene content and centromeric and telomeric KIR gene structure could be used in development of a simple algorithm to identify donors who will provide the most protection against the relapse in related HSC transplants. 
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